## Christopher S King

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8665630/publications.pdf

Version: 2024-02-01

63 5,830 21 56 papers citations h-index g-index

65 65 65 65 65 6547

times ranked

citing authors

docs citations

all docs

#	Article	IF	CITATIONS
1	Antithrombotic Therapy for VTE Disease. Chest, 2016, 149, 315-352.	0.4	4,060
2	Antithrombotic Therapy for VTE Disease. Chest, 2021, 160, e545-e608.	0.4	357
3	ldiopathic pulmonary fibrosis: effects and optimal management of comorbidities. Lancet Respiratory Medicine,the, 2017, 5, 72-84.	5.2	137
4	High-Flow Nasal Cannula Therapy in COVID-19: Using the ROX Index to Predict Success. Respiratory Care, 2021, 66, 909-919.	0.8	119
5	Pulmonary artery size as a predictor of pulmonary hypertension and outcomes in patients with chronic obstructive pulmonary disease. Respiratory Medicine, 2014, 108, 1626-1632.	1.3	75
6	Outcomes of mechanically ventilated patients with COVID-19 associated respiratory failure. PLoS ONE, 2020, 15, e0242651.	1.1	67
7	Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study. Lancet Respiratory Medicine,the, 2021, 9, 1266-1274.	5.2	62
8	Lung Transplantation for Patients With COVID-19. Chest, 2022, 161, 169-178.	0.4	54
9	The Trouble With Group 3 Pulmonary Hypertension in Interstitial Lung Disease. Chest, 2020, 158, 1651-1664.	0.4	50
10	Pulmonary artery size as a predictor of outcomes in idiopathic pulmonary fibrosis. European Respiratory Journal, 2016, 47, 1445-1451.	3.1	49
11	Identification and treatment of comorbidities in idiopathic pulmonary fibrosis and other fibrotic lung diseases. Current Opinion in Pulmonary Medicine, 2013, 19, 466-473.	1.2	42
12	Singleâ€center experience with use of letermovir for CMV prophylaxis or treatment in thoracic organ transplant recipients. Transplant Infectious Disease, 2019, 21, e13166.	0.7	40
13	Practical considerations in the pharmacologic treatment of idiopathic pulmonary fibrosis. Current Opinion in Pulmonary Medicine, 2015, 21, 479-489.	1.2	38
14	Fostamatinib for the Treatment of Hospitalized Adults With Coronavirus Disease 2019: A Randomized Trial. Clinical Infectious Diseases, 2022, 75, e491-e498.	2.9	34
15	Moving Toward a More Ideal Anticoagulant. Chest, 2013, 143, 1106-1116.	0.4	28
16	Critical Care of the Adult Patient With Cystic Fibrosis. Chest, 2019, 155, 202-214.	0.4	28
17	Treatment of pulmonary hypertension in idiopathic pulmonary fibrosis: shortfall in efficacy or trial design?. Drug Design, Development and Therapy, 2014, 8, 875.	2.0	25
18	Management of Right Heart Failure in the Critically Ill. Critical Care Clinics, 2014, 30, 475-498.	1.0	23

#	Article	IF	CITATIONS
19	Association of D-dimer and Fibrinogen With Hypercoagulability in COVID-19 Requiring Extracorporeal Membrane Oxygenation. Journal of Intensive Care Medicine, 2021, 36, 689-695.	1.3	23
20	Pulmonary hypertension due to interstitial lung disease. Current Opinion in Pulmonary Medicine, 2019, 25, 459-467.	1.2	22
21	Hemothorax following lung transplantation: incidence, risk factors, and effect on morbidity and mortality. Multidisciplinary Respiratory Medicine, 2016, 11, 40.	0.6	21
22	Prevalence and impact of WHO group 3 pulmonary hypertension in advanced idiopathic nonspecific interstitial pneumonia. European Respiratory Journal, 2018, 52, 1800545.	3.1	19
23	Antifibrotic Therapies and Progressive Fibrosing Interstitial Lung Disease (PF-ILD): Building on INBUILD. Journal of Clinical Medicine, 2021, 10, 2285.	1.0	18
24	A Phase-2 Exploratory Randomized Controlled Trial of INOpulse in Patients with Fibrotic Interstitial Lung Disease Requiring Oxygen. Annals of the American Thoracic Society, 2022, 19, 594-602.	1.5	17
25	The association between white blood cell count and outcomes in patients with idiopathic pulmonary fibrosis. Respiratory Medicine, 2020, 170, 106068.	1.3	16
26	Cardiac Support. Critical Care Clinics, 2017, 33, 777-794.	1.0	15
27	Impact of Noninvasive Respiratory Support in Patients With COVID-19 Requiring V-V ECMO. ASAIO Journal, 2022, 68, 171-177.	0.9	15
28	POINT: Should All Patients With Idiopathic Pulmonary Fibrosis, Even Those With More Than Moderate Impairment, Be Treated With Nintedanib or Pirfenidone? Yes. Chest, 2016, 150, 273-275.	0.4	13
29	Impact of the new definition for pulmonary hypertension in patients with lung disease: an analysis of the United Network for Organ Sharing database. Pulmonary Circulation, $2021, 11, 1$ -7.	0.8	13
30	HRCT evaluation of patients with interstitial lung disease: comparison of the 2018 and 2011 diagnostic guidelines. Therapeutic Advances in Respiratory Disease, 2020, 14, 175346662096849.	1.0	12
31	Differentiation of Idiopathic Pulmonary Fibrosis from Connective Tissue Disease-Related Interstitial Lung Disease Using Quantitative Imaging. Journal of Clinical Medicine, 2021, 10, 2663.	1.0	11
32	Pulmonary hypertension in idiopathic pulmonary fibrosis: epidemiology, diagnosis and therapeutic implications. Current Respiratory Care Reports, 2012, 1, 233-242.	0.6	10
33	Association Between Anticoagulation and Survival in Interstitial Lung Disease. Chest, 2021, 159, 1507-1516.	0.4	10
34	Idiopathic pulmonary fibrosis patients with severe physiologic impairment: characteristics and outcomes. Respiratory Research, 2021, 22, 5.	1.4	10
35	Derivation and validation of a simple multidimensional index incorporating exercise capacity parameters for survival prediction in idiopathic pulmonary fibrosis. Thorax, 2023, 78, 368-375.	2.7	10
36	Inhaled Nitric Oxide via High-Flow Nasal Cannula in Patients with Acute Respiratory Failure Related to COVID-19. Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine, 2021, 15, 117954842110470.	0.5	9

3

#	Article	IF	Citations
37	Early postoperative management after lung transplantation: Results of an international survey. Clinical Transplantation, 2017, 31, e12985.	0.8	8
38	A 24-Year-Old Woman With Precipitous Respiratory Failure After Lung Transplantation. Chest, 2018, 153, e53-e56.	0.4	8
39	The Role of Surgical Lung Biopsy in the Diagnosis of Fibrotic Interstitial Lung Disease: Perspective from the Pulmonary Fibrosis Foundation. Annals of the American Thoracic Society, 2021, 18, 1601-1609.	1.5	8
40	Exercise pulmonary haemodynamic response predicts outcomes in fibrotic lung disease. European Respiratory Journal, 2018, 52, 1801015.	3.1	6
41	Expert consensus on the management of adverse events and prescribing practices associated with the treatment of patients taking pirfenidone for idiopathic pulmonary fibrosis: a Delphi consensus study. BMC Pulmonary Medicine, 2020, 20, 191.	0.8	6
42	Delphi consensus recommendation for optimization of pulmonary hypertension therapy focusing on switching from a phosphodiesterase 5 inhibitor to riociguat. Pulmonary Circulation, 2022, 12, e12055.	0.8	6
43	Incidence and prognostic significance of pleural effusions in pulmonary arterial hypertension. Pulmonary Circulation, 2021, 11, 1-10.	0.8	5
44	Organ Donors. Chest, 2015, 148, 303-305.	0.4	3
45	Ventricular Diastolic Pressure Ratio as a Marker of Treatment Response in Pulmonary Hypertension. Chest, 2017, 152, 980-989.	0.4	2
46	Fungal thyroiditis in a lung transplant recipient. BMJ Case Reports, 2018, 2018, bcr-2018-227033.	0.2	2
47	Agreement Between the TEG 6s and TEG 5000 Analyzers in Extracorporeal Membrane Oxygenation. ASAIO Journal, 2021, Publish Ahead of Print, .	0.9	2
48	Development and Validation of a Clinical Diagnostic Scoring System for the Diagnosis of IPF. Annals of the American Thoracic Society, 2021, 18, 1803-1810.	1.5	2
49	Idiopathic Pulmonary Fibrosis: Phenotypes and Comorbidities. Respiratory Medicine, 2019, , 273-297.	0.1	2
50	Does 1-minute walk test predict results of 6-minute walk test in patients with idiopathic pulmonary fibrosis?. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2021, 38, e2021005.	0.2	2
51	Identifying Patients with Group 3 Pulmonary Hypertension Associated with COPD or ILD Using an Administrative Claims Database. Lung, 2022, 200, 187-203.	1.4	2
52	The impact of early de novo donor-specific antibodies on lung transplant outcomes: Is timing everything?. Journal of Heart and Lung Transplantation, 2016, 35, 1057-1058.	0.3	1
53	A 70-Year-Old Woman Presenting With Diarrhea and In-hospital Cardiac Arrest. Chest, 2018, 153, e5-e8.	0.4	1
54	A New Way of Looking at an Old Problem. Chest, 2020, 158, 31-32.	0.4	1

#	Article	IF	CITATIONS
55	Extracorporeal life support for cardiogenic shock during pregnancy and postpartum: a single center experience. Perfusion (United Kingdom), 2022, 37, 493-498.	0.5	1
56	ISHLT consensus document on lung transplantation in patients with connective tissue disease: Part II: Cardiac, surgical, perioperative, operative, and post-operative challenges and management statements. Journal of Heart and Lung Transplantation, 2021, 40, 1267-1278.	0.3	1
57	Rebuttal From Drs King andÂNathan. Chest, 2016, 150, 278.	0.4	O
58	Extracorporeal Membrane Oxygenation as a Bridge to Initial Medical Therapy in a Patient With Decompensated Pulmonary Arterial Hypertension Presenting With Biventricular Failure. Journal of Medical Cases, 2019, 10, 260-263.	0.4	0
59	63: D-Dimer and Fibrinogen Magnitude and Hypercoagulability by Thromboelastography in Severe COVID-19. Critical Care Medicine, 2021, 49, 33-33.	0.4	0
60	Outcomes of mechanically ventilated patients with COVID-19 associated respiratory failure. , 2020, 15, e0242651.		0
61	Outcomes of mechanically ventilated patients with COVID-19 associated respiratory failure., 2020, 15, e0242651.		O
62	Outcomes of mechanically ventilated patients with COVID-19 associated respiratory failure., 2020, 15, e0242651.		0
63	Outcomes of mechanically ventilated patients with COVID-19 associated respiratory failure., 2020, 15, e0242651.		O